Immunotherapy pioneer Steven A. Rosenberg, MD, PhD, has been awarded the National Medal of Technology and Innovation by President Biden. It is the nation’s highest honor for technological achievement. Dr. Rosenberg is Chief of the Surgery Branch at the Center for Cancer Research at the National Cancer Institute, part of the National Institutes of Health (NIH).
Steven A. Rosenberg, MD, PhD
Awarded by the President of the United States, the National Medal of Technology and Innovation recognizes outstanding contributions to America’s economic, environmental, and social well-being. Dr. Rosenberg received his medal from President Biden at a White House ceremony on October 24, 2023. The distinguished oncologist is among nine individuals and a team of three receiving the award this year.
Groundbreaking Research and Treatment
Dr. Rosenberg helped pioneer the development of immunotherapy. He identified the anticancer properties of interleukin-2, which became the first cancer immunotherapy approved by the U.S. Food and Drug Administration. He was also the first to identify tumor-infiltrating lymphocytes (TILs). He developed a type of treatment known as adoptive cell transfer (ACT) immunotherapy, in which TILs are extracted from a tumor, grown to large numbers in the lab, and then administered back to a patient as a “living drug” to shrink their tumors. ACT is now being developed by hundreds of academic and industrial centers to treat people with cancer.
Dr. Rosenberg was the first to introduce foreign genes into patients, a development that opened the field of human gene therapy, now being widely studied for many diseases. He was the first to use chimeric antigen receptor T cells to treat patients with aggressive lymphomas.
In recent work, a clinical trial that Dr. Rosenberg is leading on the use of TILs to selectively target cancer cells led to complete and partial shrinkage of tumors in women with metastatic breast cancer. He is also using TILs to develop personalized cancer immunotherapies for patients whose cancers do not respond to standard treatments.
